

OCT 6 - 2005



510(k) summary of safety and effectiveness information is being submitted in accordance with requirements of SMDA 1990 and 21CFR 807.92.

The assigned 510(k) number is: K052549

**ESA BIOSCIENCES, INC.  
ESA INTERNATIONAL, INC.**

22 Alpha Road  
Chelmsford, MA 01824-4171  
United States  
(978) 250-7000  
Fax (978) 250-7090  
www.esainc.com

**ESA LABORATORIES, INC.**

22 Alpha Road  
Chelmsford, MA 01824-4171  
United States  
(978) 250-7150  
Fax (978) 250-7171

**ESA ANALYTICAL, LTD.**

Brook Farm, Dorton  
Aylesbury, Buckinghamshire  
HP18 9NH England  
(4) 239381  
(844) 239382

**CYPRESS SYSTEMS**

A Division of ESA Biosciences, Inc.  
2300 West 31<sup>st</sup> Street, Suite A  
Lawrence, KS 66047  
United States  
(800) 235-2436  
Fax (785) 832-0406  
www.cypressystems.com

1. Submitter's Information

ESA Biosciences Inc  
22 Alpha Road  
Chelmsford, MA 01824 USA

Contact: Harold Asp, Quality Assurance Manager  
Phone: (978) 250-7000  
Fax: (978) 250-7090

Date Summary Prepared: September 15, 2005

2. Device Name

Product Name: LeadCare® II Blood Lead Testing System  
Classification Name: Atomic Absorption, Lead  
Common/Usual Name: Anodic Stripping Voltammetry (ASV)  
Proprietary Name: LeadCare® II Blood Lead Testing System  
Product Code: DOF

3. Predicate Device

Substantial Equivalence to ESA Bioscience Inc. (formerly ESA Inc.) LeadCare® Blood Lead Testing System. (K971640)

4. Device Description

The LeadCare® II Blood Lead Testing System is an instrumented assay utilizing electrochemistry and a unique sensor to be used for the quantitation of lead in whole human blood. Testing can be performed on venous or capillary samples. The system is comprised of an analyzer, sensor (single use, disposable), reagent vial (filled with a measured amount of Treatment Reagent) and a calibration button. The system is powered by 4 AA batteries or AC Adapter. A built in self test checks the electronic functions of the analyzer each time it is turned on. Blood lead controls are available to monitor the precision and accuracy of the system.



The methodology of the system is Anodic Stripping Voltammetry (ASV). Most lead is carried in red blood cells. When a sample of whole blood is mixed with Treatment Reagent, the lead in the red blood cells is released and made available for detection. During the Pb test, the analyzer causes the lead to collect on the sensor. After a specified time, the analyzer removes the lead accumulated on the sensor. The current response (a peak shaped curve) is baseline corrected, quantified and converted to a blood Pb value. The analyzer displays the blood Pb level in units of  $\mu\text{g/dL}$ .

The test electrode is covered by a thin layer of colloidal gold in an inert polymer matrix. The treatment reagent contains a dilute hydrochloric acid solution in water.

5. Intended Use

The LeadCare® II Blood Lead Testing System is an instrumented assay to be used in the quantitation of lead in whole human blood. The LeadCare® II System is suitable for use in a physician's office laboratory (POL).


6. Comparison to Predicate Device

The LeadCare® II Blood Lead Testing System is a modification of the LeadCare® Blood Lead Testing System and is substantially equivalent to it. The table below summarizes the similarities and differences.

Feature	LeadCare® System	LeadCare® II System
Intended Use	An Instrumented assay to be Used in the quantitation of Lead in human whole blood. The LeadCare® System is suitable for use in Physician's Office Laboratory Environment (POL)	Same as LeadCare®.
Methodology	Anodic Stripping Voltmmetry (ASV)	Same as LeadCare®.
Sample Matrix	Fresh human whole blood	Same as LeadCare®.
Blood Collection	Skin puncture or venipuncture	Same as LeadCare®.
Treatment Reagent	Dilute hydrochloric acid solution in water	Same as LeadCare®.
Sample handling	Uses 50 $\mu\text{l}$ pipette to transfer sample from reagent tube to sensor	Uses 50 $\mu\text{l}$ capillary tube to transfer sample from reagent tube to sensor



Feature	LeadCare® System	LeadCare® II System
Sensor (Test Strip)	(2)Screen printed conductive inks on an inert polymer substrate. (1) screen printed dielectric ink is for insulation and electrode area definition.	Same as LeadCare®. In addition, a plastic spacer and lid are attached to the sensors to create a channel, which fills via capillary action.
Active Test Electrode area	Test electrode is covered by a thin layer of colloidal gold in an inert polymer matrix	Same as LeadCare®.
Calibration	Electronic calibration button	Same as LeadCare®.
Check for Sensor Lot Expiration	None	Checks sensor lot expiration date passed in on the calibration button for that particular lot of sensors.
Internal Self Test	Self test checks electronic functions of analyzer each time it is turned on	Same as LeadCare®.
Sensor Connector	Makes electrical contact with sensor.	Sensor insertion detection and makes electrical contact with sensor.
Unit of Measure	Results displayed in micrograms of lead per deciliter of whole blood ( $\mu\text{g}/\text{dl}$ of Pb)	Same as LeadCare®.
Displayed Result	Pb result is displayed until the Start button is pressed. Upon power-up after auto shut-off, last result is displayed.	Pb result is displayed until a new sensor is inserted.
Reportable Range	1.4 –65 $\mu\text{g}/\text{dl}$ of Pb	Same as LeadCare®.
Controls	2 levels of external control	2 levels of external control
Power Source	AC Adapter or one 9 volt battery	AC Adapter or 4 AA batteries
On/Off	Start button acts as On switch; auto shut-off	On/Off switch and auto shut-off
Test Time	3 minutes	Same as LeadCare®.
Initiation of Test	User presses Start button after applying sample.	Analyzer starts the test after confirming enough sample has been added to the sensor.
Pb Test Algorithm	ASV routine; Pb peak identified and quantified; blood Pb result assigned using look-up tables	Same as LeadCare®.
Error Messages	5 error codes	16 error messages
Audible Tones	“Beep” at power-up; at beginning of test; at end of test; after calibration.	Same as LeadCare®.
User Interface	Custom display, limited message capability	Alphanumeric display, 4 lines by 20 characters allows useful messages to guide users through procedure



Feature	LeadCare® System	LeadCare® II System
System Operating Range	Temperature: 54°-97° F (12-36°C) Relative Humidity 12%-80% (non condensing)	Same as LeadCare®.
Sensitivity (Limit Of Detection)	1.4 µg/dl Pb	1.5 µg/dl Pb
Display Resolution	0.1 µg/dl Pb	Same as LeadCare®.

## 7. Discussion of Non-Clinical Performance Data

A method comparison study was conducted in which 108 human samples were run on six LeadCare II analyzers over 5 days and compared with results run by graphite furnace atomic absorption spectroscopy (GFAAS). Of the 108 samples, 22 were spiked (86 were unspiked).

The results from this study gave the following regression:

$$Y (\text{LeadCare II}) = 1.040 \times \text{GFAAS} + 0.12, s_{y,x} = 1.30, r = 0.996$$

The average LeadCare II bias from reference is shown in Table 1 for three ranges.

**Table 1**  
**Average LeadCare II average bias from GFAAS**

Lead concentration µg/dL	LeadCare II bias from GFAAS	LeadCare II % bias from GFAAS
0 - 10	0.07	-----
10.1 - 25.0	-----	4.7%
25.1 - 65	-----	5.0%

These results are similar to the LeadCare results, which had a regression equation of:

$$Y (\text{LeadCare I}) = 0.992 \times \text{GFAAS} + 0.94$$

Since the LeadCare II average biases are well within goals, LeadCare II is substantially equivalent to LeadCare .

## 8. Conclusions

In summary, based on comparison with the legally marketed LeadCare® Blood Lead Testing System, the data demonstrates that the LeadCare® II Blood Lead testing System performs as well as the predicate device and do not present new issues of safety and effectiveness.



OCT 6 - 2005

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Mr. Harold Asp  
Quality Assurance Manager  
ESA Biosciences Inc.  
22 Alpha Road  
Chelmsford, MA 01824

Re: k052549  
Trade/Device Name: LeadCare® II Blood Lead Testing System  
Regulation Number: 21 CFR 862.3550  
Regulation Name: Lead test system  
Regulatory Class: Class II  
Product Code: DOF  
Dated: September 15, 2005  
Received: September 16, 2005

Dear Mr. Asp:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Carol C. Benson, M.A.  
Acting Director  
Division of Chemistry and Toxicology  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K052549

Device Name: LEADCARE® II BLOOD LEAD TESTING SYSTEM

Indications For Use:

### For In Vitro Diagnostic Use Only


The LeadCare® II Blood Lead Testing System is an instrumented assay to be used in the quantitation of lead in human whole blood. The Leadcare® II System is suitable for use in a physician's office laboratory environment (POL).

Prescription Use   X   AND/OR Over-The-Counter Use             
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
\_\_\_\_\_  
Division Sign-Off

Office of In Vitro Diagnostic Device  
Evaluation and Safety

Page 1 of   1  

510(k) K052549